Sumitomo Chemical Company, Limited
Notice Regarding New Share Issuance, etc. by Our Subsidiary
Sumitomo Pharma Co., Ltd. has resolved to issue up to 59 million new shares, planning to raise approximately 116.4 billion yen. The funds raised will be allocated to research and development in the oncology field and to strengthen the financial base.
Key Figures
- Public Offering Shares: 51,304,400 shares
- Third-Party Allocation Shares: 7,695,600 shares
- Maximum Funds Raised: 116,490,277,000 yen
AI要約
Overview of Capital Policy
At the Board of Directors meeting on April 8, 2026, Sumitomo Pharma Co., Ltd. resolved to issue up to 59 million new shares (public offering and third-party allotment) and to conduct a share offering. The estimated total net proceeds upper limit is approximately 116.4 billion yen, and this will be implemented as a global offering targeting institutional investors both domestically and internationally. The issue price is scheduled to be determined between April 20 and 23, 2026.
Use of Proceeds and Impact on Shareholders
The funds raised will be applied as follows: 3 billion yen for promoting clinical trials in the oncology field, 1 billion yen for research and development in neurodegenerative diseases and infectious diseases, 1 billion yen to strengthen regenerative and cell therapy businesses, 1 billion yen for enhancing production and quality systems and IT system investments, and the remaining amount for repayment of interest-bearing debt. Although Sumitomo Chemical’s voting rights ratio will decrease, its status as a consolidated subsidiary will be maintained. Additionally, this capital increase includes plans for the initial optional redemption of hybrid bonds.
Sumitomo Chemical Company, Limited
Company overview · Stock price · Financial data · All IR
